Bafna Pharmaceuticals Ltd Stock Price Today (NSE: BAFNAPH)
Fundamental Score
Bafna Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bafna Pharmaceuticals Ltd share price today is ₹156.79, up +5.00% on NSE/BSE as of 17 June 2026. Bafna Pharmaceuticals Ltd (BAFNAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹364.97 (Cr). The 52-week high for BAFNAPH share price is ₹202.06 and the 52-week low is ₹73.01. At a P/E ratio of 34.53x, BAFNAPH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.69% and a debt-to-equity ratio of 0.36.
Bafna Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Bafna Pharmaceuticals Ltd share price chart: -4.71% return over the past month. 52-week high ₹202.06, 52-week low ₹73.01.
Bafna Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹144.30 | ₹145.41 | ₹144.30 | ₹145.41 | 6.56K (Cr) | |
| ₹138.00 | ₹138.49 | ₹134.00 | ₹138.49 | 8.65K (Cr) | |
| ₹135.50 | ₹135.50 | ₹131.10 | ₹131.90 | 926.00 (Cr) | |
| ₹130.16 | ₹136.66 | ₹125.00 | ₹129.90 | 3.65K (Cr) | |
| ₹135.84 | ₹139.40 | ₹129.05 | ₹130.16 | 6.14K (Cr) | |
| ₹139.00 | ₹140.80 | ₹135.50 | ₹135.84 | 1.39K (Cr) | |
| ₹141.80 | ₹142.33 | ₹133.01 | ₹135.03 | 2.53K (Cr) | |
| ₹139.05 | ₹140.00 | ₹133.41 | ₹135.84 | 2.14K (Cr) | |
| ₹136.40 | ₹138.50 | ₹133.50 | ₹138.36 | 2.06K (Cr) | |
| ₹137.40 | ₹138.00 | ₹133.05 | ₹134.69 | 1.21K (Cr) |
Bafna Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹138.00 | ₹145.41 | ₹134.00 | ₹145.41 | +5.37% | |
| ₹133.33 | ₹144.50 | ₹125.00 | ₹131.90 | -1.07% | |
| ₹114.80 | ₹147.95 | ₹109.00 | ₹134.00 | +16.72% | |
| ₹108.00 | ₹126.52 | ₹94.77 | ₹109.34 | +1.24% | |
| ₹118.80 | ₹131.00 | ₹102.01 | ₹106.15 | -10.65% | |
| ₹150.72 | ₹152.50 | ₹109.40 | ₹111.60 | -25.96% | |
| ₹154.28 | ₹173.26 | ₹137.48 | ₹150.72 | -2.31% | |
| ₹150.80 | ₹202.06 | ₹150.79 | ₹151.26 | +0.31% | |
| ₹172.72 | ₹176.25 | ₹132.70 | ₹143.62 | -16.85% | |
| ₹107.00 | ₹176.33 | ₹97.01 | ₹176.25 | +64.72% | |
| ₹87.70 | ₹114.97 | ₹78.18 | ₹103.86 | +18.43% | |
| ₹87.90 | ₹94.99 | ₹81.23 | ₹87.41 | -0.56% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play with regulatory headwinds and liquidity risk; Q3 beat not enough to offset concerns.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Bafna Pharmaceuticals faced scrutiny from BSE and NSE regarding share price volatility, attributing it to market conditions. The company appointed internal and cost auditors for FY 2026-27. Trading window closed on April 1, 2026, ahead of FY26 results. Stock hit lower circuit on March 24, 2026, with a 5% loss.
CORE STORY (THE REAL GAME)
Bafna is a micro-cap pharma play exposed to both domestic and export markets, attempting to scale manufacturing and navigate regulatory hurdles. The market is trying to figure out if recent volatility is a blip or a sign of deeper issues.
- Recent price volatility triggered exchange queries
- GST demand orders totaling ₹566.56 lakhs
- Closure of trading window ahead of FY26 results
- Strong Q4 FY26 results
- Successful appeal against GST demands
- New export orders in regulated markets
- Micro-cap illiquidity
- GST demand orders totaling ₹566.56 lakhs
- Outstanding foreign currency receivables of ₹205.00 lakhs
Promoter holding steady at 75%, FII at 9.34%, DII at 0.0%. No recent changes.
Indian pharma sector projected to reach $130 billion by 2030, but US market headwinds persist.
Negative free cash flow of ₹-24.67 Cr over the last 5 years.
Next 3-6 months hinge on Q4 results and resolution of GST issues. Key is whether they can maintain growth while managing regulatory risks.
Primary Thesis Risk
Inability to navigate regulatory hurdles and maintain profitability will crush the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bafna Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bafna Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BAFNAPH across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Consistent Growth Track Record (27.99% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (18.54% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (40.15% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.69%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.34%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-12.03%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-24.67 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 9.34%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bafna Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bafna Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bafna Pharmaceuticals LtdBafna Pharmaceu...Selected✓ BAFNAPH • 532989 | 49.8/100 | ₹156.79₹157 | ₹364.97₹364.97 | 34.53Average 34.5 Average | 7.69%Poor 7.69% Poor | 8.34%Poor 8.34% Poor | 0.36Excellent 0.4 Excellent | 40.15%Excellent 40.15% Excellent | 27.99%Excellent 27.99% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Bafna Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for BAFNAPH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.76 | ₹150.72 | 85.6x |
| FY 2024 | ₹3.11 | ₹78.90 | 25.4x |
| FY 2023 | ₹4.79 | ₹92.00 | 19.2x |
| FY 2022 | ₹2.21 | ₹100.75 | 45.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Bafna Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for BAFNAPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-12.03%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
19.08%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
27.99%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
40.15%
Compounded annual net profit growth over 5 years
Bafna Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BAFNAPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Bafna Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bafna Pharmaceuticals Ltd (BAFNAPH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Bafna Pharmaceuticals Ltd
About BAFNAPH (Bafna Pharmaceuticals Ltd)
Bafna Pharmaceuticals Ltd is a global pharmaceutical company dedicated to the development, manufacturing, and marketing of high-quality finished pharmaceutical formulations. Rooted... in a commitment to innovation and patient well-being, the company focuses on producing a diverse portfolio of medicines designed to address a wide spectrum of therapeutic needs. With a strong emphasis on quality control and adherence to international regulatory standards, Bafna Pharmaceuticals ensures the safety and efficacy of its products. Their manufacturing processes are rigorously monitored, employing state-of-the-art technology to maintain the highest levels of precision and consistency. Bafna Pharmaceuticals has a significant international presence, exporting its pharmaceutical formulations to numerous countries spanning diverse continents. Their extensive distribution network ensures that vital medications reach patients in regions including Europe, Australia, Africa and Asia. This broad reach highlights their dedication to improving global healthcare access and underscores their role as a reliable provider of essential medicines in diverse markets. The company continually strives to strengthen its international partnerships, building collaborative relationships with healthcare providers and distributors to better serve the evolving needs of patients worldwide. Headquartered in Chennai, India, Bafna Pharmaceuticals leverages its strategic location and established infrastructure to drive its operations and maintain its competitive edge. The company benefits from its strong Indian roots while simultaneously embracing a global outlook, fostering a culture of innovation and continuous improvement. As a subsidiary of SRJR Lifesciences LLP, Bafna Pharmaceuticals draws upon the resources and expertise of its parent company, further enhancing its capabilities and supporting its long-term growth objectives within the dynamic pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
BAFNAPH Share Price: Frequently Asked Questions
What is the current share price of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd (BAFNAPH) trades at ₹156.79 on NSE and BSE. Market cap ₹364.97 (Cr). Educational data only.
What is the P/E ratio of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has a P/E of 34.53x vs industry average 31.77x.
What is the Bull Run score for Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has a Bull Run score of 49.8/100 based on 25+ financial parameters.
Does Bafna Pharmaceuticals Ltd pay dividends?
Bafna Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has ROE of 7.69%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has debt-to-equity of 0.36.
Is Bafna Pharmaceuticals Ltd a good investment?
Bull Run gives Bafna Pharmaceuticals Ltd a score of 49.8/100. This is not investment advice — consult a SEBI-registered advisor.